Press Release Details

BERKELEY, Calif., Aug 07, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a clinical-stage biopharmaceutical company that discovers and develops novel products to prevent and treat infectious diseases, today announced that Deborah A. Smeltzer, Vice President, Operations and Chief Financial Officer, is planning to retire by year-end.

"Over the past 5 years Deborah has made valuable contributions to our business, ranging from capital formation, to partnership negotiation, to providing leadership for Dynavax Europe," commented Dino Dina, M.D., President and Chief Executive Officer of Dynavax. "One of Deborah's key contributions has been the building of a highly qualified team to assume her responsibilities, ensuring a smooth transition for the Company. It is always very difficult to accept the departure of a loyal colleague, but we support her personal decision and wish her the best in her retirement."

Dynavax also announced the promotion of Jennifer Lew to Vice President, Finance. With 15 years of experience, Ms. Lew is currently the Company's Controller and Principal Accounting Officer and joined Dynavax in December 2004. Previously, Ms. Lew was with QRS Corporation as Assistant Controller from 2002 to 2004 and Director of Finance from 2000 to 2002. Ms. Lew, who is a Certified Public Accountant, began her career at Ernst & Young in 1994.

About Dynavax

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company's lead product candidate is HEPLISAV^TM, a Phase 3 investigational adult hepatitis B vaccine designed to provide more rapid and increased protection with fewer doses than current licensed vaccines. For more information visit www.dynavax.com.

SOURCE: Dynavax Technologies Corporation

Dynavax Technologies Corporation
Amy Figueroa, 510-665-7211
Investor Relations and Corporate Communications
afigueroa@dynavax.com

Copyright Business Wire 2009